A Phase 2 interventional study of Daratumumab and Durvalumab in Multiple Myeloma, sponsored by Celgene. Terminated at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 87th largest by enrollment, is one of 7 that started in 2016, is one of 73 in phase 2, and was the 15th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 75th largest by enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2016, is one of 24 in phase 2, and was the 95th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will also explore the safety and efficacy of the addition of pomalidomide + dexamethasone to durvalumab + daratumumab (PD3).
On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA was based on data related to risks of anti-programmed cell death-1 (PD-1) antibody, pembrolizumab, in combination with IMiDs® immunomodulatory drugs in patients with multiple myeloma. As a result, enrollment into this study has been discontinued. Subjects who are receiving clinical benefit, based on the discretion of the investigator, may remain on study treatment after being reconsented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle * IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward
Drug: Daratumumab · Drug: Durvalumab
* Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle * IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward * oral POM at 4mg/day on days 1 to 21 * oral/IV dex at 40mg/day (\>75 years old) or 20mg/day (\>75 years old) on days 1, 8, 15 and 22
Drug: Daratumumab · Drug: Durvalumab · Drug: Pomalidomide · Drug: Dexamethasone
Overall Response Rate (ORR)
Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. ORR was calculated as the percent of responders (multiplied by 100). Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.
Time frame: From first dose to up to approximately 66 months
Number of Participants With Adverse Events (AEs)
Number of participants who experienced at least one adverse event. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition should be considered an AE.
Time frame: From first dose to 90 days after last dose (up to approximately 58 months)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants who experienced at least one serious adverse event. An SAE is any AE occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, constitutes an important medical event.
Time frame: From first dose to 90 days after last dose (up to approximately 58 months)
Time-To-Response (TTR)
Time-to-response is calculated as the time from enrollment to the first date of documented response (partial response or better). Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. For those participants where POM + DEX were added, time-to-response was calculated from the date POM and DEX were added to the first date of documented response (PR or better).
Time frame: From enrollment to earliest documented response (up to approximately 66 months)
Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm
Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
Time frame: From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)
Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm
Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease progression as determined by the investigator. Participants who are alive or lost to follow-up will be censored on the last-known-to-be-alive date. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.
Time frame: From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm
Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
Time frame: From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm
Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
Time frame: From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)
Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
Time frame: Cycle 1 - Days 2, 8, 15, 22
Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
Time frame: Cycle 1 - Days 2, 8, 15, 22
Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
Time frame: Cycle 1 - Days 2, 8, 15, 22
Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
Time frame: Cycle 1 - Days 2, 8, 15, 22
| Milestone | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| Started | 32 | 5 |
| Participants in the d2 arm who also received pomalidomide + dexamethasone | 7 | 0 |
| Completed | 0 | 0 |
| Not completed | 32 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Progressive disease | 30 | 3 |
| Withdrew: Other reasons | 1 | 1 |
Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. ORR was calculated as the percent of responders (multiplied by 100). Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.
| Percentage of participants | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| Overall Response Rate (ORR) | 53.1 | 75.0 |
Number of participants who experienced at least one adverse event. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition should be considered an AE.
| Participants | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 31 | 5 |
Number of participants who experienced at least one serious adverse event. An SAE is any AE occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, constitutes an important medical event.
| Participants | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 17 | 2 |
Time-to-response is calculated as the time from enrollment to the first date of documented response (partial response or better). Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. For those participants where POM + DEX were added, time-to-response was calculated from the date POM and DEX were added to the first date of documented response (PR or better).
| Weeks | Simon Stage 1: D2 Arm | Simon Stage 1: D2 + Pomalidomide + Dexamethasone | PD3 Arm |
|---|---|---|---|
| Time-To-Response (TTR) | 4.29 (4.0 to 12.0) | 5.07 (4.1 to 8.1) | 8.14 (4.3 to 8.3) |
Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
| Months | Simon Stage 1: D2 Arm | Simon Stage 1: D2 + Pomalidomide + Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm | 8.31 (3.7 to 11.1) | 8.41 (3.7 to 12.0) |
Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease progression as determined by the investigator. Participants who are alive or lost to follow-up will be censored on the last-known-to-be-alive date. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.
| Months | PD3 Arm |
|---|---|
| Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm | 7.62 (6.7 to 17.5) |
Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
| Months | Simon Stage 1: D2 Arm | Simon Stage 1: D2 + Pomalidomide + Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm | 5.74 (2.0 to 6.5) | 8.05 (3.7 to 12.9) |
Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
| Months | PD3 Arm |
|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm | 9.02 (6.9 to 18.5) |
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
| ug/mL | Simon Stage 1: D2 Arm |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm | 315.806 ± 34.832 |
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
| Hour | Simon Stage 1: D2 Arm |
|---|---|
| Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm | 1.150 (1.03 to 1.83) |
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
| Hour*ug/mL | Simon Stage 1: D2 Arm |
|---|---|
| Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm | 77831.751 ± 48.535 |
Pharmacokinetics of Durvalumab derived from serum concentration versus time data.
| Hour*ug/mL | Simon Stage 1: D2 Arm |
|---|---|
| Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm | 83966.099 ± 46.115 |
Collected over All-cause mortality was assessed from the participant's first dose to their study completion (up to approximately 66 months). SAEs and Other AEs were assessed from first dose to 90 days after last dose of study therapy (up to approximately 58 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Simon Stage 1: D2 Arm | 11/32 (34.4%) | 17/32 (53.1%) | 31/32 (96.9%) |
| PD3 Arm | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Event | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| SepsisInfections and infestations | 0/32 | 2/5 |
| PneumoniaInfections and infestations | 7/32 | 1/5 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/32 | 1/5 |
| General physical health deteriorationGeneral disorders | 3/32 | 0/5 |
| PyrexiaGeneral disorders | 2/32 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 1/32 | 0/5 |
| DeathGeneral disorders | 1/32 | 0/5 |
| FatigueGeneral disorders | 1/32 | 0/5 |
| Oedema peripheralGeneral disorders | 1/32 | 0/5 |
| HepatitisHepatobiliary disorders | 1/32 | 0/5 |
| Event | Simon Stage 1: D2 Arm | PD3 Arm |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 7/32 | 4/5 |
| AnaemiaBlood and lymphatic system disorders | 16/32 | 3/5 |
| NeutropeniaBlood and lymphatic system disorders | 15/32 | 3/5 |
| DiarrhoeaGastrointestinal disorders | 9/32 | 3/5 |
| Upper respiratory tract infectionInfections and infestations | 3/32 | 3/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/32 | 2/5 |
| NauseaGastrointestinal disorders | 8/32 | 2/5 |
| FatigueGeneral disorders | 4/32 | 2/5 |
| Respiratory tract infectionInfections and infestations | 6/32 | 2/5 |
| Neutrophil count decreasedInvestigations | 0/32 | 2/5 |
| Age, Continuous(Years) | Simon Stage 1: D2 Arm | PD3 Arm | Total |
|---|---|---|---|
| Mean | 63.2 ± 7.58 | 63 ± 5.66 | 63.2 ± 7.29 |
| Sex: Female, Male(Participants) | Simon Stage 1: D2 Arm | PD3 Arm | Total |
|---|---|---|---|
| Female | 13 | 1 | 14 |
| Male | 19 | 4 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Simon Stage 1: D2 Arm | PD3 Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 32 | 5 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Simon Stage 1: D2 Arm | PD3 Arm | Total |
|---|---|---|---|
| White | 31 | 5 | 36 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jan 2022, 65 months.
Results were first posted in Feb 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daratumumab · Durvalumab